Clinical Trial Update: Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update evaluating molecular residual disease interception in locoregionally advanced HPV+ and HPV- head and neck squamous cell carcinoma …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Squamous Cell Carcinoma

Snippet

Sponsor: University Health Network, Toronto | Conditions: Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC) | Phase 2 | Status: RECRUITING